Background. Abnormal glucose metabolism in HIV-infected patients has largely been attributed to the use of protease inhibitors. However, most studies of glucose metabolism in HIV-infected patients have focused on men or have lacked appropriate control groups.
HAART has resulted in a dramatic decrease in mortality among HIV-infected individuals [1] . Because people with HIV infection live longer, they are likely to experience diseases of midlife, including type 2 diabetes. Several studies have reported an increased prevalence of impaired glucose tolerance (IGT) and diabetes among HIV-infected individuals [2, 3] . These disorders have been largely attributed to protease inhibitor (PI) therapy [4, 5] ; however, other antiretroviral agents and classic risk factors for diabetes, including obesity, phys-ical inactivity, and genetic background, may also have contributory roles. To date, most studies of glucose metabolism in HIV-infected patients have focused on men or have lacked HIV-negative control groups. One study that included both women with and women without HIV infection found that PI use was associated with an increased risk of incident diabetes [6] , but the study was limited by the fact that a screening blood test was not used to detect diabetes. The factors associated with undiagnosed diabetes and undiagnosed IGT among middle-aged, HIV-infected women are not known.
The mechanism by which HIV-infected patients develop glucose intolerance is not completely understood. Insulin resistance among HIV-infected patients has been commonly described and has alternately been attributed to a direct inhibitory effect on cellular glucose transport by PIs [7, 8] or to HAART-associated changes in fat distribution [9] . Impaired insulin secretion in HIV-infected patients has been less well-studied, although some data suggest an association between PI use and defects in B cell function [3, 10] . The relative contributions of PI use, fat distribution, and other factors to insulin resistance and impaired insulin secretion in HIV-infected patients have not been determined.
The objective of the present study was to determine the associations of HIV, HAART, and other factors with prevalent diabetes in a cohort of middle-aged women with or at risk for HIV infection. In addition, we performed an oral glucose tolerance test (OGTT) to measure glucose and insulin levels among a subset of women without a previous diagnosis of diabetes to identify factors associated with abnormal glucose tolerance, insulin resistance, and impaired insulin secretion.
METHODS

Study participants.
We performed a cross-sectional analysis of factors associated with previously diagnosed diabetes among 620 women participating in the Menopause Study (Ms.), an ongoing longitudinal study of menopause and its sequelae in women with or at risk for HIV infection. Participant recruitment and study design have been described elsewhere [11] . Briefly, between September 2001 and January 2003, a total of 332 HIV-infected and 288 HIV-uninfected women were enrolled from the community in the Bronx, New York. Enrollment was guided so that 50% of women were HIV infected and 50% were HIV uninfected; within each group, 50% reported illicit drug use in the past 5 years, and 50% reported other high-risk behaviors. Ms. participants are followed-up with semi-annual research visits, at which standardized interviews are administered, blood samples are obtained for HIV serology and T lymphocyte studies, and weight, height, and waist circumferences are measured.
Interview data. Interview data, including medical history, antiretroviral use, family history, sociodemographic characteristics, and drug use behaviors, were collected during research visits. At each visit, participants were asked whether they had received a diagnosis of diabetes (i.e., high blood sugar level) other than during pregnancy, what their age was at the time of the diagnosis of diabetes, and whether they had taken medication for diabetes. Participants were administered the CAGE questionnaire [12] , with a positive response to у2 items indicating alcoholism [13] . Current illicit drug use was defined as use within the past 6 months. Physical activity was defined as moderate or strenuous exercise for у20 min on 11 day/ week. Menopausal status was based on self-reported bleeding patterns, with perimenopause defined as having skipped 1-11 periods during the past year and postmenopause defined as cessation of menses for у12 months [14] .
Metabolic substudy enrollment. Between June 2002 and December 2003, Ms. participants were screened for enrollment in the metabolic substudy during research visits. To be enrolled in the substudy, women had to meet criteria for 1 of the following enrollment groups: (1) the HIV-uninfected group; (2) the HIV-infected and antiretroviral-naive group; (3) the HIVinfected, PI-naive group currently receiving HAART (hereafter, "non-PI HAART"); or (4) the HIV-infected group currently receiving HAART that includes a PI (hereafter, "PI-HAART"). Participants were ineligible for inclusion in the substudy if they reported a history of diabetes, were taking antidiabetic medications, were pregnant, or had poor venous access. The substudy was approved by the institutional review boards for the protection of human subjects of Montefiore Medical Center and Albert Einstein College of Medicine (Bronx, NY). All participants provided written, informed consent.
OGTT. Following enrollment, metabolic substudy participants underwent an OGTT, which was performed according to World Health Organization procedures [15] at the Einstein General Clinical Research Center (Bronx, NY). Participants were instructed to take their morning dose of medications with water and to report to the medical center after an overnight fast lasting 10-16 h. At the medical center, 75 g of dextrose in water was administered orally during a period of !5 min. Blood samples were obtained for determination of glucose and insulin levels immediately before and 30 and 120 min after the ingestion of dextrose. Waist and hip circumferences were measured.
Assays. Specimens to be used for the determination of insulin levels were collected in iced, heparinized tubes. Plasma was separated within 20 min of collection and was stored at Ϫ70ЊC until the day of the assay. Plasma insulin levels were measured by double-antibody radioimmunoassay in the Hormone Assay Core of the Einstein Diabetes Research and Training Center (intra-assay coefficient of variance, 7.2%; interassay coefficient of variance, 9.4%; cross-reactivity with proinsulin, 36.8%). Specimens for glucose level determination were collected in tubes with glycolytic inhibitors. Plasma glucose was measured by the hexokinase method.
Data analysis. For participants in the metabolic substudy, additional outcome measures were insulin resistance, insulin secretion, and an abnormal result of OGTT (i.e., a result consistent with IGT or diabetes). IGT and diabetes were determined using American Diabetes Association criteria, which define IGT as a fasting glucose level of !126 mg/dL and a 120-min glucose level that is у140 mg/dL but !200 mg/dL during an OGTT and define diabetes as a fasting glucose level of у126 mg/dL or a 120-min glucose level of у200 mg/dL [16] . Insulin resistance was calculated using the homeostasis model assessment: [fasting insulin [17] . Insulin (mU/mL) ϫ fasting glucose (mmol/L)]/22.5 secretion was calculated using the 30-min incremental ratio of insulin to glucose ( ) [18] . DI /DG 30 30 Multivariate logistic regression analysis was performed to assess independent predictors of abnormal results of OGTT. In constructing multivariate models, we included enrollment group (i.e., HIV-uninfected group; HIV-infected, antiretroviralnaive group; HIV-infected group receiving non-PI HAART; and HIV-infected group receiving PI-HAART), as well as factors whose univariate tests yielded a P value of р.2. Comparisons of anthropometric parameters, glucose and insulin levels, insulin resistance, and insulin secretion for the enrollment groups and other factors of interest were performed using analysis of variance or Kruskal-Wallis tests. For insulin resistance and insulin secretion, analysis of covariance was performed using SAS software, version 8.1 (SAS Institute), to adjust the effect of possible confounding factors on the observed mean differences. These analyses were based on the ranks of the dependent variable, as these variables were not normally distributed. SPSS software, version 10.0 (SPSS), was used for all other analyses. Statistical significance was determined using 2-tailed tests.
RESULTS
Study participants.
The characteristics of the study cohort are shown in table 1. Of 620 participants, 332 (54%) were HIV infected. Diabetes risk factors were common; a total of 458 (74%) had a body mass index (BMI) of у25, a total of 82 (13%) had delivered a baby weighing 14.08 kg, and, of 546 participants with available data, a total of 242 (44%) had a first-degree relative with diabetes. Compared with HIV-infected women, HIV-uninfected participants had a higher prevalence of obesity, which was defined as a BMI of у30 (59% vs. 32%; ), and a higher mean waist circumference (mean ‫ע‬ P ! .0005 SEM, 98.4 ‫ע‬ 0.9 cm vs. 93.3 ‫ע‬ 0.8 cm;
).
The majority of HIV-infected participants (268, or 81%) received a diagnosis of HIV infection у5 years before enrollment in the study, and most of the HIV-infected participants (287, or 86%) were antiretroviral experienced. Of 215 participants with a history of PI use, 146 (68%) had taken nelfinavir, 93 (43%) had taken indinavir, 58 (27%) had taken ritonavir, 57 (26%) had taken lopinavir/ritonavir, 53 (25%) had taken saquinavir, 12 (6%) had taken amprenavir, and 1 (0.5%) had taken atazanavir. The median duration of PI use was 32 We further examined the relationship between methadone use and previously diagnosed diabetes by calculating the odds of having diabetes for each quartile of current methadone dose. Compared with women taking 10-60 mg of methadone daily, the adjusted OR (adjusted for BMI, HIV, and HAART use) was 3.4 (95% CI, 0.6-18.8) for women taking 61-90 mg daily, 6.8 (95% CI, 1.3-35.5) for women taking 91-120 mg daily, and 9.7 (95% CI, 1.9-49.6) for women taking 121-200 mg daily.
Metabolic substudy participants. Of 221 participants, 88 (40%) were HIV uninfected; 31 (14%) were HIV infected and antiretroviral naive; 34 (15%) were HIV infected and were receiving non-PI HAART; and 68 (31%) were HIV infected and were receiving PI-HAART. Among the 34 participants receiving non-PI HAART, 21 (62%) were receiving a nonnucleoside reverse transcriptase inhibitor and у2 nucleoside reverse-transcriptase inhibitors (NRTIs), and 13 (38%) were receiving у3 NRTIs only. Among the 68 participants receiving PIs, 25 (37%) were receiving nelfinavir, 18 (26%) were receiving lopinavir/ ritonavir, 14 (21%) were receiving ritonavir, 13 (19%) were receiving indinavir, 8 (12%) were receiving saquinavir, 3 (4%) were receiving amprenavir, and 1 (1%) was receiving atazanavir. The median duration of PI use was 42.5 months (IQR, 28.5-66.0 months).
Anthropometrics and OGTT results. The anthropometric and metabolic characteristics of the substudy participants are shown in table 3. Compared with HIV-uninfected participants, Prevalence of newly diagnosed IGT and diabetes. Twentysix participants (12%) had an OGTT result that was consistent with IGT, and an additional 13 participants (6%) had a result that was consistent with diabetes. Three women (23%) with newly diagnosed diabetes had a fasting glucose level of !126 mg/dL. Compared with HIV-uninfected women, women receiving non-PI HAART were more likely to have IGT (26% vs.
9%;
). Among HIV-infected women, there was no dif-P p .02 ference in the prevalence of IGT or diabetes according to HAART or PI use.
Factors associated with an abnormal result of OGTT. pack-years). These estimates were essentially unchanged when women with a history of using megestrol ( ), prednisone n p 1 ( ), or estrogen and/or progesterone ( ) were exn p 3 n p 12 cluded. There was no association between glucose tolerance and CD4 + cell count, delivering a baby weighing 14.08 kg, use of illicit drugs or methadone, alcoholism, or BMI, even when waist-to-hip ratio was removed from the model.
Factors associated with insulin resistance. Compared with other enrollment groups, insulin resistance was greatest among women receiving non-PI HAART ( r p 0.426 P ! .0005 lated with insulin resistance. There was no association between insulin resistance and age, family history of diabetes, or illicit drug use. In a model controlling for HIV infection, receipt of HAART, and PI use, factors independently associated with insulin resistance were waist circumference ( ), Hispanic P ! .0001 ethnicity ( ), and physical activity ( ). After con-P p .01 P p .03 trolling for race/ethnicity, physical activity, and CD4
+ count in a model including HIV-infected women only, waist circumference ( ) and non-PI HAART ( ) were indepen-P ! .0001 P p .03 dently associated with insulin resistance. In both models, substitution of BMI for waist circumference did not alter the results. Models excluding women with a history of steroid or hormone use had similar results.
Factors associated with insulin secretion. Insulin secretion (mU/mL ϫ mg/dL Ϫ1 ) was lowest among participants with diabetes and highest among participants with normal glucose tolerance (  ,  for diabetes 2.14 ‫ע‬ 0.18 P p .04 cocaine use were correlated; therefore, 2 separate multivariate models were constructed: one containing data for current opiate use (i.e., heroin or methadone) and one containing data for current cocaine use. In a model controlling for enrollment group, factors associated with lower insulin secretion included current opiate use ( ) and older age ( ). The model con-P p .02 P p .03 taining current cocaine use had similar results ( ). P p .02
DISCUSSION
In this cohort of predominantly black and Hispanic middleaged women with or at risk for HIV infection, risk factors for diabetes were common: 74% of participants had a BMI of у25, 79% were physically inactive, 44% had a first-degree relative with diabetes, and 13% had delivered a baby that weighed 14.08 kg. Thus, not surprisingly, the 13% prevalence of previously diagnosed diabetes in this cohort is higher than the rate of 1% found among women aged 40-55 years participating in the Study of Women's Health Across the Nation (SWAN), a multiethnic, multicenter study of the menopausal transition [19] . Despite this high prevalence, additional cases of diabetes and IGT were detected by use of OGTT among a substantial number of participants. When we extrapolated the OGTT results from the metabolic substudy to the entire cohort, we estimated that the prevalence of undiagnosed diabetes was 5% and of the prevalence of undiagnosed IGT was 10%. These findings suggest that abnormal glucose metabolism is a major health problem for middle-aged women with or at risk for HIV infection.
Previous cohort studies in which screening tests for diabetes were not performed found an independent association between PI use and incident hyperglycemia or diabetes [5, 6] . Using an OGTT, we found that non-PI HAART, and not PI-HAART, was associated with IGT and insulin resistance. These contradictory findings may reflect differential screening practices; given clinicians' awareness of the association between use of PIs and diabetes, they may be more likely to screen for, and therefore to diagnose, diabetes among PI-treated patients. Alternatively, these findings may suggest that HAART, in general-rather than solely PI use-is associated with glucose intolerance in HIVinfected persons. Although indinavir has been associated with early direct effects on insulin sensitivity [10, 20] , recent studies have demonstrated that other PIs differ in their ability to induce insulin resistance [21] [22] [23] . Furthermore, in a study of treatment-experienced patients, Hadigan et al. [9] found that fat redistribution, and not PI use, was associated with IGT and diabetes. Although we did not assess peripheral lipoatrophy, in our cohort of mostly overweight or obese women, truncal adiposity, as measured by waist circumference [24] , was strongly associated with insulin resistance.
Both opiate use and cigarette smoking were associated with abnormal glucose metabolism. Women receiving methadone were nearly twice as likely to have previously diagnosed diabetes, compared with women who were not receiving methadone. Furthermore, current opiate use was associated with lower insulin secretion. The dose-response relationship between methadone and the odds of having previously diagnosed diabetes suggests a direct association between opiate use and glucose metabolism. Also supporting this association are experimental studies that found that opiate use impaired insulin secretion and glucose tolerance [25] [26] [27] . Alternatively, opiate use may be a marker of hepatitis C, a risk factor for diabetes [28, 29] that was not assessed in the present study. Our finding that the number of pack-years of smoking was associated with abnormal glucose tolerance is consistent with studies of HIVuninfected individuals that demonstrate an association between insulin resistance and smoking [30, 31] .
We have demonstrated that diabetes and IGT affect a major proportion of middle-aged women with or at risk for HIV, particularly those who use opiates. Given the high prevalence of obesity, physical inactivity, and family history of diabetes in this population, it is likely that the burden of disease will increase as these women age. Currently, the International AIDS Society-USA guidelines for diabetes screening among HIVinfected individuals target patients who have been treated with PIs [32] . On the basis of our findings, we recommend the expansion of screening for diabetes by HIV care providers to include patients with classic risk factors for diabetes, including being overweight, having a family history of diabetes, and having delivered a baby that weighed 14.08 kg [16] . In addition, interventions aimed at ameliorating modifiable risk factors, including obesity and physical inactivity, should be implemented in HIV primary care settings.
